Johnson & Johnson (JNJ) Sees FY13 Revs at $70.4B - $71.1B; Est. at $71.1B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Goldman Maintains Sell on Johnson & Johnson (JNJ); Drug Business Spin Still Unlikely
April 17, 2013 10:49 AM EDTGoldman Sachs maintained a Sell rating on Johnson & Johnson (NYSE: JNJ) with a price target of $80.00. Analyst Jami Rubin reiterated his view that Johnson & Johnson should consider a break up, though he does not think management will consider this option.
... More
Johnson & Johnson (JNJ) Tops Q1 EPS by 3c; Reaffirms FY EPS Outlook
April 16, 2013 7:47 AM EDTJohnson & Johnson (NYSE: JNJ) reported Q1 EPS of $1.44, $0.03 better than the analyst estimate of $1.41. Revenue for the quarter came in at $17.5 billion versus the consensus estimate of $17.46 billion.
Johnson & Johnson still sees FY 2013 EPS $5.35-$5.45, versus the consensus of $5.40.
... More
